Johnson & Johnson has announced encouraging results from its pivotal Phase 2/3 ENERGY study evaluating IMAAVY (nipocalimab-aahu) in patients with warm autoimmune hemolytic anemia (wAIHA), a rare autoimmune blood disorder that currently has no FDA-approved therapies. The findings suggest that the investigational treatment could offer a much-needed targeted option for patients struggling with chronic anemia and severe fatigue.
According to the study results presented in Stockholm, patients receiving the 30 mg/kg dose of IMAAVY achieved a statistically significant durable hemoglobin response compared with placebo. Improvements in hemoglobin levels were observed as early as the first week of treatment, highlighting the drug’s rapid onset of action. Researchers also reported greater reductions in fatigue symptoms and decreased reliance on corticosteroids among treated patients.
Warm autoimmune hemolytic anemia occurs when the body's immune system mistakenly produces antibodies that attack and destroy red blood cells, leading to anemia, fatigue, and potentially life-threatening complications. Current management largely relies on broad immunosuppressive therapies, which are not specifically approved for the condition and often carry significant side effects.
IMAAVY works by blocking the neonatal Fc receptor (FcRn), reducing levels of harmful IgG autoantibodies that drive disease activity while aiming to preserve essential immune functions. This targeted mechanism has attracted significant interest as a potential new approach for autoimmune diseases.
The positive ENERGY trial results further strengthen the regulatory case for IMAAVY. Earlier this year, the U.S. FDA granted Priority Review to the supplemental Biologics License Application seeking approval of the therapy for wAIHA, recognizing the urgent need for effective treatments in this underserved patient population. If approved, IMAAVY could become the first FDA-approved therapy specifically indicated for warm autoimmune hemolytic anemia.
